UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

Their core work

UKE is one of Germany's leading university hospitals, combining clinical medicine with deep neuroscience and cardiovascular research. They run large-scale clinical trials in stroke treatment and heart failure, while simultaneously pursuing fundamental brain research — from synaptic plasticity and optogenetics to computational neuroscience and brain simulation. Their translational pipeline spans from molecular biology (liquid biopsies, microRNA biomarkers) through neuroimaging to patient-facing interventional trials, making them both a research powerhouse and a clinical validation site for European health projects.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), UKE focused on fundamental molecular biology — bone remodeling (ROR2BONE), stem cell cardiology (EHT-CaMKII), HIV vaccines (EHVA), and early optogenetics/cancer cell capture work. From 2018 onward, a clear pivot toward computational neuroscience and large-scale brain simulation emerged, driven by deepening involvement in the Human Brain Project ecosystem (neuroinformatics, HPC, neuromorphic computing). Simultaneously, their clinical trial portfolio matured toward data-driven, biomarker-guided medicine — diabetes omics, liquid biopsies, and precision stroke treatment.

UKE is converging computational brain modeling with clinical data science, positioning itself at the intersection of digital neuroscience infrastructure and biomarker-driven clinical trials.

How they like to work

UKE operates as a dual-mode partner: they coordinate nearly half their projects (29 of 64), showing strong leadership capacity, particularly in focused ERC/MSCA grants where a single PI drives the research. At the same time, they join large multinational clinical consortia (EHVA, BEAt-DKD, PRECIOUS) as specialist clinical or neuroimaging sites. With 596 unique partners across 45 countries, they function as a highly connected hub — expect a well-organized partner with established project management infrastructure and experience across both small PI-driven grants and large multi-site trials.

UKE has collaborated with 596 distinct partners across 45 countries, making it one of the most broadly connected university hospitals in H2020. Their network is pan-European with significant reach into global health partnerships (Latin America via SCALA, HIV research via EHVA).

What sets them apart

UKE combines a working hospital with a top-tier neuroscience research program and active participation in Europe's largest brain simulation initiative — few clinical institutions can bridge bedside medicine and computational brain modeling at this scale. Their dual strength in running interventional clinical trials (stroke, cardiovascular) AND operating advanced neuroimaging and optogenetics labs makes them a rare partner who can take a finding from the microscope to the patient cohort within one institution. For consortium builders, UKE offers both scientific depth and clinical validation infrastructure under one roof.

Highlights from their portfolio

• PSYCHOCELL
  EUR 2M ERC grant coordinated by UKE investigating how neuronal network abnormalities cause neuropsychiatric disorders — their largest single-PI project and a pillar of their optogenetics program.
• TENSION
  EUR 1.1M coordinator role in a major randomized clinical trial on stroke thrombectomy in extended time windows — demonstrates their ability to lead high-impact, patient-facing European trials.
• HBP SGA1
  Part of the Human Brain Project flagship, connecting UKE to Europe's largest neuroscience infrastructure initiative spanning neuroinformatics, HPC, and brain simulation — despite modest direct funding, this positions them in a uniquely powerful research network.